This is a preview of subscription content, log in via an institution to check access.
Notes
2019 US dollars
Reference
Wallace K, et al. The Budget Impact of Including Rucaparib on a US Payer Formulary for the Treatment of Patients with Metastatic Ovarian Cancer. PharmacoEconomics : 4 Nov 2020. Available from: URL: http://doi.org/10.1007/s40273-020-00970-y
Rights and permissions
About this article
Cite this article
Including rucaparib in US payer formulary has little budget impact. PharmacoEcon Outcomes News 866, 18 (2020). https://doi.org/10.1007/s40274-020-7278-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7278-3